In conclusion, the results of this study suggest that 18F-FDG PET is a precious tool for predicting pathological response and prognosis of patients with primary unresectable HCC after treated by Lenvatinib combined with PD-1 inhibitors as conversion therapy. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.